FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 56823

News■ Unclear/unknown

Leads To Development Joins Clarenta Group, Strengthening Early-Stage Drug Development Expertise

EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 08:00 UTC
LAST UPDATE2026-09-30 08:00 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Private biotech services acquisition; no public ticker or deal terms disclosed.

Private biotech roll-up, no public read
CATALYST TO WATCH

None for listed markets

MAIN RISK

No disclosed valuation

FULL DISPATCH

LONDON, Sept. 30, 2026 /PRNewswire/ -- Clarenta today announced that Leads To Development (L2D) has joined Clarenta Group following a majority investment, strengthening Clarenta's ability to support biotech and pharmaceutical sponsors from preclinical drug development strategy through...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-09-30 08:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.